Updated:
GalaxyBiomedical Investment
GalaxyBiomedical Investment was established in 1993 in Beihai, China, as a subsidiary of YH Group. Chairman Keyang Liu leads the firm, with co-founder Huang...
GalaxyBiomedical Investment
GalaxyBiomedical Investment was established in 1993 in Beihai, China, as a subsidiary of YH Group. Chairman Keyang Liu leads the firm, with co-founder Huang Jian having previously served as Chairman and Legal Representative. The firm's corporate structure ties its fortunes to the operating performance of its core biomedical holdings while leaving room for opportunistic diversification into industrial and real-asset categories. Portfolio companies include Nanjing Galaxy Biotechnology and Suzhou Galaxy Biomedical, which anchor a biopharma vertical focused on China's domestic market. Beyond biomedicine, the firm holds interests in distribution equipment and electronic components. A notable non-healthcare asset is the Galaxy Software Technology Park, a commercial real estate project on Xizang Road in Beihai. The firm draws on tight operational relationships with Beijing Teamsun Technology — linked through shared directorships — and with the China Venture Capital Research Institute, where executives serve on the East China Representative Office. Through subsidiary Liuzhou Special Transformer, GalaxyBiomedical holds a director-unit seat within the Transformer Branch of the China Electricity Industry Association, signaling a meaningful industrial manufacturing tilt. The firm's geographic footprint is concentrated in China's southern corridor, with headquarters in Beihai, operating entities in Nanjing and Suzhou, and a manufacturing presence in Liuzhou. No publicly disclosed AUM or deployment figures exist, which is characteristic of a holding company that measures itself by subsidiary revenue rather than third-party capital. The firm's structural identity is its operating-company DNA: it is not a pure financial allocator but a parent with direct control over subsidiaries that generate cash flows for reinvestment. This creates a permanent-capital base and a decision-making timeline that ignores fund cycles. Succession appears to rest with Keyang Liu, who holds both the Chairmanship and Board Secretary role, concentrating governance in a single executive.
General information
Firm type
Corporate Investor
Year founded
1993
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beihai
Corporate office
Beihai, Guangxi, China
Principals
Keyang Liu
Chairman and Secretary of the Board
Huang Jian
Former Chairman and Legal Representative
Sector focus
Frequently asked questions
Who controls investment decisions at GalaxyBiomedical?
Chairman Keyang Liu holds the dual role of Chairman and Secretary of the Board, concentrating both strategic and governance authority. Co-founder Huang Jian previously served as Chairman and Legal Representative. No separate CIO or investment committee has been disclosed, suggesting Liu exercises primary decision-making power over capital allocation.
Is GalaxyBiomedical a pure-play biomedical investor?
No. While the firm controls Nanjing Galaxy Biotechnology and Suzhou Galaxy Biomedical, its portfolio extends into distribution equipment, electronic components, and commercial real estate via the Galaxy Software Technology Park. It also has ties to the industrial transformer sector through subsidiary Liuzhou Special Transformer.
What is GalaxyBiomedical's relationship with YH Group?
GalaxyBiomedical Investment was established as a subsidiary of YH Group in 1993. YH Group is the parent entity; GalaxyBiomedical operates as an investment and holding company underneath it. The exact ownership percentage or control mechanics between the two have not been publicly detailed.
Does GalaxyBiomedical invest in venture-stage biotech or only mature operating companies?
The firm's disclosed holdings — Nanjing Galaxy Biotechnology and Suzhou Galaxy Biomedical — are established operating companies, not early-stage startups. No venture-capital activity, seed investments, or incubator programs have been publicly documented. The posture appears to favor control or majority stakes in revenue-generating subsidiaries.
Which external partners does GalaxyBiomedical co-invest or collaborate with?
Close relationships exist with Beijing Teamsun Technology, linked through shared directorships, and with the China Venture Capital Research Institute, where GalaxyBiomedical executives sit on the East China Representative Office. The subsidiary Liuzhou Special Transformer holds a director-unit seat in the Transformer Branch of the China Electricity Industry Association. No fund-level co-investment partnerships have been disclosed.
Does GalaxyBiomedical manage third-party capital or operate any external funds?
No evidence suggests the firm accepts outside limited-partner commitments. It is structured as a corporate investor — a subsidiary holding company deploying the parent's own balance sheet. This aligns with the absence of any publicly listed fund vehicles, AUM figures, or fundraising notices.
How is GalaxyBiomedical governed, and what is the succession plan?
Governance is concentrated in Chairman Keyang Liu, who serves as both Chairman and Secretary of the Board. Co-founder Huang Jian previously served as Chairman and Legal Representative and has stepped back from those roles. No publicly documented succession plan or independent board structure exists, which is consistent with many privately held Chinese corporate investors of this vintage.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: